Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.3%

1 terminated out of 30 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed with results

Key Signals

5 with results94% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (2)
P 1 (4)
P 2 (10)
P 3 (3)

Trial Status

Completed15
Recruiting7
Unknown3
Not Yet Recruiting2
Withdrawn1
Terminated1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT06349668Phase 3Recruiting

Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery

NCT00902590Active Not Recruiting

A Genotype-Phenotype Urothelial Cancer Registry

NCT02122172Phase 2Terminated

Afatinib in Advanced Refractory Urothelial Cancer

NCT03291028Recruiting

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

NCT04028479Completed

The Registry of Oncology Outcomes Associated with Testing and Treatment

NCT06598761RecruitingPrimary

Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

NCT06652022Not ApplicableRecruiting

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

NCT06469229Not Yet Recruiting

Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria

NCT01326871Phase 1Completed

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT06427993Not Yet Recruiting

Urine DNA Methylation Detection for Hematuria Evaluation

NCT04625556Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

NCT03520231Phase 2Completed

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

NCT05043662Unknown

UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.

NCT01846520Not ApplicableCompleted

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT04197414Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

NCT02665039Phase 2Completed

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

NCT02300610Phase 1Completed

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

NCT01191892Phase 2Completed

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

NCT01844947Phase 1Completed

Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Scroll to load more

Research Network

Activity Timeline